

Biosafety Regulation: Lessons from Kenya and the Philippines

From the STEPS Centre project: Beyond Biosafety

STEPS^{centre}

STEPS briefing

More reading

Beyond Biosafety: project webpage www.steps-centre.org/ourresearch/ biosafety.html

Regulatory harmonization and agricultural biotechnology in Argentina and China: Critical assessment of state-centered and decentered approaches, Regulation & Governance (2010), by Paddy Van Zwanenberg, Adrian Ely, Adrian Smith, Chen Chuanbo, Ding Shijun, Maria-Eugenia Fazio and Laura Goldberg www.steps-centre.org/PDFs/Regulation Governance2010.pdf

Africa's biotechnology battle, Ian Scoones and Dominic Glover, Nature, 13 August 2011 http://www.steps-centre.org/ourresearch/ gm.html

For other STEPS Centre briefings and working papers, see www.steps-centre. org/publications

Credits

This briefing was written by Sally Brooks and edited by Nathan Oxley.



About the STEPS Centre

The STEPS Centre (Social, Technological and Environmental Pathways to Sustainability) is an interdisciplinary global research and policy engagement hub uniting development studies with science and technology studies. We aim to develop a new approach to understanding, action and communication on sustainability and development in an era of unprecedented change. The STEPS Centre is based at the Institute of Development Studies and SPRU Science and Technology Policy Research at the University of Sussex with a network of partners in Asia, Africa and Latin America and is funded by the Economic and Social Research Council.

Contact us

STEPS Centre, Institute of Development Studies, University of Sussex, Brighton BN1 9RE, UK Tel: +44 (0)1273 915673 ask for Harriet Dudley Email: steps-centre@ids.ac.uk Website: www.steps-centre.org Both Kenya and the Philippines have been regarded as 'test cases' for biotechnology and biosafety regulatory development in their respective regions.

Biosafety and its regulation has become the lightning rod for debates about the governance of transgenic (GM) crops in

developing countries. This focus has tended to narrow policy debates about agricultural biotechnology to the control and management of physical risk. Questions about which technologies are most appropriate, or how to manage their socioeconomic impacts, tend to be sidelined.



Nick Francis / Maize seeds / Speak-It Films

The STEPS Centre conducted research between 2007 and 2010 on biosafety regulation in Argentina, China, Kenya and the Philippines. In November 2010 we convened a workshop in Nairobi to provide a forum for regulators and other stakeholders from the Philippines and Kenya to share lessons in biosafety regulation. This briefing draws on the research to outline challenges for Kenya and other countries moving to implement legislation on biotechnology.

Flexibility – but for whom?

Both Argentina and China have used the flexibilities that exist in international regulations when developing and implementing their own rules. In Argentina this flexibility was used to support the commercial farming sector. In China, it was used to support domestic GM seed industries. But in neither country has this flexibility been used to respond to the needs of smallholder farmers. Indeed, in both countries, small farmers' circumstances and problems are not well recognized by regulation.

Involving civil society

In Argentina and China, civil society organisations have been largely absent from debates about transgenic crops and their regulation. By contrast, in the Philippines, civil society organisations (CSOs) play an important role.

The National Biosafety Committee of the Philippines, the first in ASEAN, was established in 1990. Even today it is one of the few biotechnology regulatory bodies in the world that includes civil society representatives. Twenty years on, however, both state regulators and civil society organisation face new challenges associated with increasing levels of scientific and regulatory complexity.

CSOs engaging in biosafety debates in the Philippines today pursue a range of complementary advocacy strategies. These include: national campaigns (e.g. GMO labelling); local advocacy (lobbying for alternative regulatory pathways at the provincial level, such as an organic agriculture ordinance and a GMO ban ordinance); and the provision of technical support to state regulators in intergovernmental negotiations.

Kenya: implementing the law

In Kenya, the Biosafety Bill (the third in Africa after South Africa and Burkina Faso) became law in February 2009, following a lengthy and polarised debate. By contrast, in the Philippines, both state regulators and civil society organisations (CSOs) had lobbied for an executive order rather than a law, in order to avoid a protracted parliamentary debate and maintain flexibility in the regulatory system.

Kenya now faces the challenge of implementing the law. A key lesson from our workshop was that, once the implementation phase begins, there is a shift in emphasis from regulations (on paper) to practice (in the laboratory, greenhouse and field). The challenge for CSOs in Kenya is now to understand how regulation is done in practice.

Similarly, public engagement needs to take place at multiple levels, not just in the capital. The most important forum for public engagement in the Philippines has been public hearings up and down the country.

Challenges for Kenya:

- Who benefits from flexibility? The examples of Argentina and China show that flexibility at the national level doesn't necessarily translate into better policies for farmers. There are many claims on the 'public interest'. Unless there is a conscious focus on smallholder farmers, their needs will be sidelined.
- Contexts matter. What are the implications of commercialising GM crops for small holder farmers? Answering this question means acknowledging informal practices of seed-saving and exchange. This is not just an issue of biosafety regulation:

coordination is needed across all seedrelated policies, including those concerning intellectual property.

• What role for civil society organisations? As Kenya moves to the implementation stage, civil society organisations need to engage more with the detail of regulatory assessment. This takes time, effort and resources. It means CSOs have to make choices about what role(s) best match their mandate and expertise, and they need to work together to complement each others' strengths and strategies.



Nick Francis / Kenyan landscape / Speak-it Films

Biosafety regulation in Kenya – defining moments

1990 Government appointed "National Committee on Biotechnology Advances and their Applications" initiates an evaluation of biotechnology.

1991 Virus resistant sweet potato research begins at the Kenyan Agricultural Research Institute (KARI).

1993 DGIS Netherlands programme founds and starts Kenyan Agricultural Biotechnology Platform.

1998 Guidelines for biosafety published by the National Council for Science and Technology (NCST)

1999 Biosafety framework established via UNEP-GEF project. Insect Resistance Maize for Africa research begins (CIMMYT, KARI, Novartis). **2000** Government of Kenya signs Cartagena Protocol on Biosafety.

2003 National Biosafety Committee (NBC) approves research and contained trials on Bt cotton and virus resistant cassava. Draft Biosafety Bill prepared.

2006 National Biotechnology Policy approved by cabinet.

2007 Private motion against Biosafety Bill is debated in parliament.

2008 Programme for Biosafety Systems begins (USAID/IFPRI). Lobbying for and against Biosafety Bill intensifies in and out of parliament. Water Efficient Maize for Africa (WEMA) project launched (Monsanto, KARI, CIMMYT, AATF). Biosafety Bill passed by parliament.

2009 Biosafety Bill receives presidential ascent and becomes law. Drafting of regulations and institutionalisation of National Biosafety Authority (NBA) begins.